Notification of grant:Divisional EPO patent
Notification of grant: Divisional EPO patent
Adam Robertson new Chief Scientific Officer in Regenics
 Adam Robertson has today signed up as  Chief Scientific Officer for Regenics AS.  Adam is part of the team that develops cutting  edge skin care and wound healing at Regenics.  Adam...
Regenics Board Meeting No 4 2018
November 7th 2018
Bernat Rocarols - R&D Engineer Regenics
Regenics Board Meeting No 3 2018
September 9th 2018
EPO National validation 2018
EPO Patent validation 
Regenics Board Meeting No 2 2018
June 13th 2018
Protocol Annual Meeting 2018
June 28th 2018 Protocoll of Regenics Annual Meeting on June 28th 2018. The Annual Meeting 2018 took place in the Companys office, Karvesvingen. 2, Oslo
US patent granted June 2018
Upcoming event: 37C Health Meeting Stavanger
Regenics AS attends the 37C "Digitalization in Health" meeting on June 19-20 of June 2018 at Forus Stavanger. CEO Henrik Lund, co-chairs the meeting    
Regenics AS Annual Report 2017
Regenics post a small positive 2017 result with topline in excess of 0.047 mill NOK. 
Notice of Annual Meeting June 28th 2018
June 13th 2018 Notice of Annual Meeting June 28th 2018. The Annual Meeting 2018 will take place at the Companys site Karvesvingen 2. 2, Oslo from 2 pm to 5 pm.
Innovation Norway grants Innovation Contract to Regenics AS
Regenics AS was May 18th 2018 awarded an Innovation Contract from Innovation Norway. The Innovation Contract has a total budget of 14.3 million NOK to support the development of Vernex®...
Updated share info May 7th 2018
Regenics AS provides updated share info and shareowner distribution as per May 7th 2018
Regenics Board Meeting No 1 2018
March 2nd 2018
Protocol from Extraordinary Annual Meeting December 15th 2017
December 15th 2017 Protocoll of Extraordinary Annual Meeting December 15th 2017. The Annual Meeting 2017 took place in the Companys office, Karvesvingen. 2, Oslo

<<  <   Page 2 of 7   >  >>

Regenics AS has developed a number of assays and techniques to study effects of various substances on skin cells both in vitroin vivo and in the clinic. Our focus is to develop products and techniques for therapeutic skin applications and to improve skin appearance.